Real world glycemic effectiveness of linagliptin (Tradjenta®) among type 2 diabetes mellitus adults by age and renal function.

Study identification

• EU PAS number:
  EUPAS21548
• Study ID:
  22317
• Official title and acronym:
  Real world glycemic effectiveness of linagliptin (Tradjenta®) among type 2 diabetes mellitus adults by age and renal function.
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  No information provided.
• Study status:
  Finalised

Research institutions and networks

Institutions

Boehringer Ingelheim

Study timelines

Date when funding contract was signed

Actual:16/06/2017

Study start date

Planned:21/11/2017

Actual:21/11/2017

Data analysis start date

Planned:12/01/2018

Actual:01/12/2017

Date of final study report

Planned:30/03/2018

Actual:04/02/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer-Ingelheim & Eli Lilly & Co

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable